Navigation Links
SenesTech, Inc. Commences Product Registration Process With Australian Government
Date:11/10/2008

FLAGSTAFF, Ariz., Nov. 10 /PRNewswire/ -- SenesTech, Inc. has launched the regulatory process to register both the active ingredient and the first ContraPest(R) product with the government of Australia. In parallel with laboratory research and testing in the rice field rat species, registration of ContraPest(R) bait will open the door for marketing this unique rodent population management product to the agricultural ministries of Southeast Asia. ContraPest(R) will target the rice field rat, a major rodent pest species for rice agriculture in this region, known to eat or damage a significant portion of rice crops each year.

ContraPest(R) works through disruption of the reproductive potential of female rodents by selectively eliminating the female's supply of egg cells. The direct effect will be to drastically reduce the number of rats in the field. This translates to increased rice yield, and since nearly half of the world's population depends on rice for sustenance, a 10 percent increase in rice yield will feed approximately 380 million people per year. A further benefit to this humane approach to pest population control is the reduced potential for disease, since rodents and their carcasses are vectors for many human illnesses, some life-threatening.

The regulatory process for ContraPest(R) has been initiated with the Australian Pesticides and Veterinary Medicines Authority (APVMA), the Australian agency responsible for oversight of all agricultural chemical and related products that are manufactured or used in Australia. This registration process will be guided by direct consultation with regulatory expertise within the Australian government.

"The APVMA largely sets the standards for agricultural product use in Australasia, so gaining registration by the APVMA will mean nearly instantaneous acceptance of the product by governments with rice-based agriculture across the region," says Timothy L. Vail, Ph.D., Vice President of Manufacturing and Regulations for SenesTech, Inc. "Just as FDA approval is critical for pharmaceuticals in the U.S., moving ContraPest(R) through the regulatory process with the APVMA will secure our ability to manufacture the product under Australian governmental oversight using Good Manufacturing Practices. This guarantees a high standard of product quality and consistency, regardless of a particular manufacturer's location."

For additional information contact Everett Hale at ehale@senestech.com or visit http://www.senestech.com. ContraPest(R) is projected to be available for commercial use in the spring of 2010.

ABOUT: (SenesTech, Inc.) SenesTech is a platform technology company located in Flagstaff, Arizona on the Northern Arizona Center for Emerging Technology campus. SenesTech specializes in environmentally neutral fertility control products for companion animals and wildlife population control.


'/>"/>
SOURCE SenesTech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
2. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
3. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
4. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
5. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
6. Phase 1b/2a Program Commences for RVX-208
7. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
8. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
9. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. Arbios Commences Process to Seek European Marketing Approval for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
Breaking Biology News(10 mins):